Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects the bone marrow. The study is investigating the effectiveness of two treatments: Iberdomide and Isatuximab. Iberdomide is a medication taken in capsule form, while Isatuximab is given as an injection. The purpose of the study is to compare the effects of using Iberdomide alone versus using it in combination with Isatuximab after patients have undergone a procedure called autologous hematopoietic stem-cell transplantation, which is a type of stem cell transplant using the patient's own cells.

Participants in the study will receive either Iberdomide alone or Iberdomide combined with Isatuximab as maintenance therapy. Maintenance therapy is a treatment given to help keep cancer from coming back after it has been treated. The study will last for up to two years, during which time the researchers will monitor the patients to see how well the treatments work in keeping the cancer from returning. The main goal is to see if the combination of Iberdomide and Isatuximab is more effective than Iberdomide alone in achieving a state called minimal residual disease (MRD) negativity, which means that there are no detectable cancer cells in the bone marrow.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to track the effectiveness of the treatments. The study aims to provide valuable information that could improve treatment options for patients with Multiple Myeloma in the future. Participants will be randomly assigned to one of the treatment groups, and some may receive a placebo, which is a substance with no active medication, to help compare the results accurately. The findings from this study could lead to better understanding and management of Multiple Myeloma.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be required to provide written informed consent. This ensures understanding of the trial's nature and potential consequences.

    Eligibility criteria include prior participation in a related trial, a confirmed diagnosis of multiple myeloma, and having undergone specific treatments such as high-dose melphalan therapy and autologous stem cell transplantation.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm the patient's response to previous treatments and overall health status. This includes evaluating the patient's performance status and ensuring compliance with the study's pregnancy prevention program.

  3. Step 3

    Randomization

    The patient will be randomly assigned to one of two groups: one receiving iberdomide alone, and the other receiving iberdomide plus isatuximab.

  4. Step 4

    Treatment phase

    The treatment phase involves the administration of medications over a two-year period.

    Patients in the iberdomide group will take iberdomide orally in capsule form. Dosages may vary, including 1 mg, 0.75 mg, or 0.45 mg, depending on the specific protocol.

    Patients in the iberdomide plus isatuximab group will receive iberdomide as described above, along with isatuximab administered as a subcutaneous injection.

  5. Step 5

    Monitoring and follow-up

    Throughout the treatment phase, regular monitoring will occur to assess the patient's response to therapy and any side effects. This includes periodic evaluations of bone marrow to determine minimal residual disease (MRD) status.

    Patients will be required to abstain from donating blood and, if applicable, adhere to specific guidelines regarding pregnancy prevention.

  6. Step 6

    Completion of treatment

    After two years of maintenance therapy, the treatment phase concludes. Final assessments will be conducted to evaluate the primary endpoint, which is the rate of MRD negativity.

    Secondary endpoints, such as progression-free survival, will also be assessed to determine the overall effectiveness of the treatment.

Who can join the trial?

12 criteria

  • Patients must have been part of a previous trial called GMMG-HD8/DSMM XIX, which included a confirmed diagnosis of **multiple myeloma** with specific symptoms or markers and measurable disease before starting treatment.
  • Patients must agree not to donate blood while taking the study treatment and for 28 days after stopping the treatment.
  • Patients must be able to understand the nature and consequences of the clinical trial.
  • Patients must provide written informed consent before joining the trial.
  • Patients must have received at least one cycle of high-dose **melphalan therapy** and **autologous stem cell transplantation**. Melphalan therapy is a type of chemotherapy, and autologous stem cell transplantation is a procedure where a patient's own stem cells are used to replace damaged or destroyed bone marrow.
  • Patients must have shown at least a **Partial Response** to treatment according to specific criteria at the time of joining the trial. A Partial Response means the disease has improved but is not completely gone.
  • Patients must be 18 years or older when joining the trial.
  • Patients must have a **WHO performance status** of 0, 1, or 2. This status is a measure of a patient's general well-being and ability to carry out daily activities, with 0 being fully active and 2 being able to do self-care but unable to work.
  • Females who can have children must have two negative pregnancy tests before starting the study treatment and agree to ongoing pregnancy testing. They must either commit to complete abstinence from heterosexual contact or use two forms of birth control during the study and for 28 days after the last dose of the study drug.
  • Male participants must practice complete abstinence or use a condom during sexual contact with a pregnant female or a female who can have children while taking the study drug and for 28 days after the last dose, even if they have had a vasectomy.
  • Males must agree not to donate sperm while on the study treatment and for 28 days after the last dose.
  • All participants must follow the requirements of the **Pregnancy Prevention Program**.

Who cannot join the trial?

3 criteria

  • Patients who have a different condition than multiple myeloma cannot participate. Multiple myeloma is a type of cancer that affects certain cells in the bone marrow.
  • Patients who are not within the specified age range cannot participate. The age range for this study is typically adults.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups like children, pregnant women, or those unable to give consent.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Iberdomide

    is a medication being studied for its potential to help patients with newly diagnosed multiple myeloma. It is used as a maintenance therapy after patients have undergone a procedure called autologous hematopoietic stem-cell transplantation. The goal of using iberdomide is to reduce the amount of cancer cells remaining in the bone marrow, which is known as minimal residual disease.

  • Isatuximab

    is another medication included in the trial, used in combination with iberdomide. Isatuximab is an antibody therapy that targets specific proteins on the surface of cancer cells, helping the immune system to identify and destroy these cells. The combination of isatuximab with iberdomide is being tested to see if it is more effective than using iberdomide alone in achieving better outcomes for patients with multiple myeloma.

What is already known about the treatment

  • Iberdomide

    Iberdomide is administered orally and is currently being studied in clinical trials for its effectiveness in treating multiple myeloma. It is primarily used as a maintenance therapy following autologous stem-cell transplantation. The medication works by modulating the immune system, specifically targeting proteins that regulate immune responses, which helps in reducing cancer cell growth. Iberdomide is classified as an immunomodulatory drug.

  • Isatuximab

    Isatuximab is given through intravenous infusion and is also under investigation in clinical trials for multiple myeloma treatment. It is used in combination with other therapies to enhance treatment outcomes. Isatuximab functions by binding to a specific protein on the surface of cancer cells, leading to their destruction by the immune system. It is classified as a monoclonal antibody.

Investigated diseases

Multiple Myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. These cancerous plasma cells multiply rapidly, leading to an overproduction of abnormal proteins that can cause damage to bones, kidneys, and the immune system. As the disease progresses, it can result in bone pain, fractures, anemia, and increased susceptibility to infections. The accumulation of these abnormal cells can also lead to a decrease in the production of normal blood cells, causing fatigue and other related symptoms. Over time, the disease can cause significant complications, affecting various organs and systems in the body.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-507402-13-00Protocol codeGMMG-HD9/DSMM XVIIIEstimated enrolment451 patientsSponsorUniversitaetsklinikum Heidelberg AöR

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.